logo-loader
viewHikma Pharmaceuticals PLC

Hikma Pharmaceuticals and Arecor strike a second strategic partnership deal

Arecor Limited's Sarah Howell talks to Proactive London about the announcement to expand their agreement with Hikma Pharmaceuticals PLC (LON:HKMA) to co-develop ready-to-administer injectable medicines in the US to a second product.

As Howell explains, this deal follows on from the first agreement signed in January to develop a product using Arecor’s proprietary drug formulation technology platform Arestat.

Howell hints that there could be a potential third deal in the pipeline considering the 'strength of this collaboration'.

Quick facts: Hikma Pharmaceuticals PLC

Price: 2608 GBX

AIM:HIK
Market: AIM
Market Cap: £6.01 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Pan African Resources expands investor base with OTCQX upgrade, reveals...

Pan African Resources plc (LON:PAF) (OTCQX:PAFRY) CEO Cobus Loots tells Proactive that the South African-based gold-mining group upgraded to trade its shares on the OTCQX Best Market, because he feels the group has a lot to offer to US investors in terms of its profits, dividends, and growth,...

10 hours, 5 minutes ago

2 min read